Company intelligence / Profile preview
Targanta Therapeutics Corporation
Cambridge, Massachusetts, USAthemedicinescompany.com ↗
- Ownership
- Private
- Employees
- ~82
- Development stage
- Phase 3
01
Overview
Targanta’s lead product candidate was oritavancin—a novel semi-synthetic glycopeptide antibiotic acquired from InterMune—which demonstrated potent activity against a broad spectrum of resistant and susceptible Gram-positive bacteria. Two pivotal Phase 3 trials for cSSSI met primary endpoints with efficacy and improved safety compared to standard therapy. The company also developed a preclinical platform for targeted delivery of antibiotics to bone tissue. In 2009, before commercial launch of its products, Targanta was acquired by The Medicines Company.[1][4]
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecules (antibiotics)prodrugsglycopeptides
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Targanta Therapeutics Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Targanta Therapeutics Corporation.